DELRAY BEACH, Fla., Oct. 25, 2016 (GLOBE NEWSWIRE) — PositiveID Corporation (“PositiveID” or “Company”) (OTCQB:PSID), a life sciences company focused on detection and diagnostics, announced today that its Chief Technology Advisor, Dr. Kimothy Smith, was selected to chair the Healthcare Innovation Panel at the National Defense Industrial Association Health Affairs Biodefense Summit in Washington, D.C.
Dr. Smith is the Senior Director for the Applied Innovation Center for Advanced Analytics, Desert Research Institute, and Professor of Microbiology and Epidemiology, at the University of Nevada School of Community Health Sciences. He was previously Senior Advisor for International Biodefense for the Department of Homeland Security, Office of Health Affairs and was detailed to the U.S. State Department Office of International Health and Biodefense. He consults in the areas of biosurveillance, bioforensics, biodefense, biosecurity, molecular genetics and diagnostics, and food safety, defense and security.
As Chief Technology Advisor of PositiveID, Dr. Smith assists with the development and testing of PositiveID’s Firefly Dx, a point-of-need (“PON”), handheld system designed to deliver molecular diagnostic results from a sample in less than 30 minutes, compared to hours or even days for a lab device, using real-time PCR (polymerase chain reaction) chemistry. Firefly’s applications include PON, lab-quality, detection of pathogenic organisms; agricultural and food screening in both domestic sectors and developing countries; and detection of biological agents associated with weapons of mass destruction.
The Health Affairs Division of the National Defense Industrial Association, established in 1996, maintains its focus on areas relating to policymaking, planning, programming and regulation of health care technology. The division also considers the related areas of research and development, technology modeling and simulation, procurement, military medicine, software and health care providers.
About PositiveID Corporation
PositiveID Corporation is a life sciences tools and diagnostics company with an extensive patent portfolio. PositiveID develops biological detection and diagnostics systems, specializing in the development of microfluidic systems for the automated preparation of and performance of biological assays. PositiveID is also a leader in the mobile technology vehicle market, with a focus on the laboratory market and homeland security. For more information on PositiveID, please visit http://www.psidcorp.com, or connect with PositiveID on Twitter, Facebook or LinkedIn.
Statements about PositiveID’s future expectations constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID’s actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the Company’s ability to complete the development of Firefly Dx, as well as other risks. Additional information about these and other factors that could affect the Company’s business is set forth in the Company’s various filings with the Securities and Exchange Commission, including those set forth in the Company’s 10-K filed on April 12, 2016, and 10-Qs filed on August 12, 2016, May 16, 2016, and November 12, 2015, under the caption “Risk Factors.” The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.